Bcl-2 family proteins are often dysregulated in cancer, contributing to the survival of malignant cells. Overexpression of anti-apoptotic members such as Bcl-2 and Bcl-xL is commonly observed in various cancers, helping cancer cells evade apoptosis and resist chemotherapy. Targeting these proteins with specific inhibitors is a promising therapeutic strategy in cancer treatment.
